Considerations in designing systems for large scale production of human cardiomyocytes from pluripotent stem cells by Allen Chen et al.
Chen et al. Stem Cell Research & Therapy 2014, 5:12
http://stemcellres.com/content/5/1/12REVIEWConsiderations in designing systems for large
scale production of human cardiomyocytes from
pluripotent stem cells
Allen Chen, Sherwin Ting, Jasmin Seow, Shaul Reuveny and Steve Oh*Abstract
Human pluripotent stem cell (hPSC)-derived
cardiomyocytes have attracted attention as an
unlimited source of cells for cardiac therapies. One of
the factors to surmount to achieve this is the production
of hPSC-derived cardiomyocytes at a commercial or
clinical scale with economically and technically feasible
platforms. Given the limited proliferation capacity of
differentiated cardiomyocytes and the difficulties in
isolating and culturing committed cardiac progenitors,
the strategy for cardiomyocyte production would be
biphasic, involving hPSC expansion to generate adequate
cell numbers followed by differentiation to cardiomyocytes
for specific applications. This review summarizes and
discusses up-to-date two-dimensional cell culture,
cell-aggregate and microcarrier-based platforms for
hPSC expansion. Microcarrier-based platforms are
shown to be the most suitable for up-scaled production
of hPSCs. Subsequently, different platforms for directing
hPSC differentiation to cardiomyocytes are discussed.
Monolayer differentiation can be straightforward and
highly efficient and embryoid body-based approaches
are also yielding reasonable cardiomyocyte efficiencies,
whereas microcarrier-based approaches are in their
infancy but can also generate high cardiomyocyte
yields. The optimal target is to establish an integrated
scalable process that combines hPSC expansion and
cardiomyocyte differentiation into a one unit operation.
This review discuss key issues such as platform selection,
bioprocess parameters, medium development,
downstream processing and parameters that meet
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Cardiovascular disease is the leading cause of death
globally, accounting for 244.8 per 100,000 deaths in 2008
[1]. Although novel drugs and devices have enhanced the
quality of life for patients with cardiovascular disease, they
have not necessarily decreased morbidity or mortality [2].
Human adult cardiomyocytes have a turnover rate of less
than 1% per year [3], indicating a limited regenerative
capacity of the human adult heart. Resident cardiac stem
cells and cardiac progenitor cells have been reported in the
heart [4,5] and they have the ability to differentiate into all
the constituent cell lineages of the myocardium, therefore
participating in the repair process of a myocardial injury
[6]. However, these cells cannot restore very large infarcts
and an external therapeutic intervention is needed to
compensate the heart’s inadequate intrinsic repair ability.
As such, heart transplantation currently remains the only
definitive treatment for end-stage patients. Unfortunately,
donor hearts are critically deficient; thus, new therapeutic
paradigms for heart failure are warranted.
A potential cure for heart failure can be achieved through
cardiovascular cell therapy, which aims to repopulate
damaged myocardium with new contractile cells and re-
store the heart. Pluripotent stem cells have nearly unlimited
self-renewal capability in vitro and have the ability to differ-
entiate into all three germ layers, thus giving rise to all cell
types of the human body [7]. Since the initial demonstra-
tion that contracting cardiomyocytes can be generated from
both human embryonic stem cells (hESCs) [8] and human
induced pluripotent stem cells (hiPSCs) [9], stem cell
technology has raised hopes for a source of unlimited
numbers of human cardiomyocytes to rebuild the heart. In
experimental animal models of acute myocardial infarction,
injury site has been shown to benefit heart function
[10-12]. It was shown that the functional improvement of
the heart is transient and presumably due to paracrine
contributions of transplanted hESC-derived cardiomyocytestd. The licensee has exclusive rights to distribute this article, in any medium, for
time, the article is available under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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results presented so far are heartening because they present
a prospect for survival and maturation of cardiomyocytes
[14]. In cases of myocardial infarction, one billion cells
potentially need to be replaced [15], emphasizing the need
for reproducible and high yield differentiation protocols.
Besides their significance in regenerative medicine, cardi-
omyocytes generated in vitro are also needed for cardiac
safety pharmacology testing. Unforeseen cardiotoxicity is
one of the most common causes of late-stage clinical attri-
tion [16]. Many drugs in the market have been withdrawn
due to unexpected drug-induced electrophysiological alter-
ations of the heart [17]. An example is the well-known case
of rofecoxib, which was withdrawn from the market due to
concerns about increased risk of cardiotoxicity and stroke
associated with long-term, high dosage use. The early
detection of any drug side effects can halt the process of
futile and cost-intensive drug development and, more
importantly, safeguard the health of patients. However,
physiologically relevant in vitro cardiac models are limited
as no current immortalized human cell lines accurately re-
semble functional cardiomyocytes of the heart for assessing
preclinical cardiotoxic responses of drugs. Current cardiac
models are typically animal models and in vitro assays,
which lack cross-species translation due to differences in
biological pathways and pharmacokinetic properties. Stud-
ies have already shown that hiPSC-derived cardiomyocytes
will react to cardioactive drugs with expected responses,
supporting the concept of large scale human cell-based
predictive toxicology screens [18]. The use of human pluri-
potent stem cell (hPSC)-derived cardiomyocytes offers the
pharmaceutical industry a precious tool for accelerating
clinical introduction, reduce drug development costs and,
most importantly, improving drug safety. Currently, GE
Healthcare (GE Healthcare PTE Ltd., Singapore, Singapore)
is providing cryopreserved hPSC-derived cardiomyocytes
(Cytiva™ Cardiomyocyte). GE Healthcare has demonstrated
that these cardiomyocytes can be used to develop a multi-
plexed cell imaging-based cardiotoxicity assay with fluores-
cent probes measuring plasma membrane integrity, cellular
calcium levels, cell number and mitochondria status.
A third application of hPSC-derived cardiomyocytes is
drug discovery. Over the years, many animal models, par-
ticularly mouse, have been generated and widely used. Al-
though these models have shed light on our understanding
of the onset and progression of cardiac diseases, they do not
always recapitulate the phenotype seen in patients. Several
studies have demonstrated the usage of hiPSC-derived cardi-
omyocytes as models for human cardiac disease [19-21].
Leveraging on models of cardiomyopathies, hPSC-derived
cardiomyocytes can thus serve as a platform for screening
existing therapies, testing experimental drug combinations
and developing new ones. As high-content screens usually
require more than 108 purified cells [22], challenges toovercome are scalable differentiation methods and
purification of cell fractions of interest.
The immense potential of hPSC-derived cardiomyocytes
in regenerative medicine, cardiotoxicity pharmacology test-
ing and drug discovery is indeed tantalizing. To effectively
serve these applications, however, a reproducible, efficient
and cost-effective platform for in vitro cardiomyocyte
generation must be developed.
In this review, we examine the progress in development
of large scale cardiomyocyte differentiation platforms from
hPSCs. We describe the performance of existing reported
systems and summarize the main obstacles for further
research and optimization.Expansion of human pluripotent stem cells and
cardiogenesis
The limited proliferating capacity of differentiated cardio-
myocytes dictates the design of the production process. It is
possible to isolate and cultivate cardiac progenitors as
shown in several studies using fluorescence-activated cell
sorting of the KDR+/PDGFRA- population [23] or genetic-
ally modified NKX2-5 reporter cell line [24]. Even though
these progenitors have the potential to be used directly for
cell therapy and as the source for cardiomyocyte gener-
ation [25], their isolation, maintenance requirements and
expansion capacity provide several challenges. Wang and
colleagues [26] have comprehensively reviewed the use of
cardiac progenitors for cell therapy. Further, the differenti-
ation step of hPSCs to cardiomyocytes has a limited cell
expansion of two- to five-fold [27,28]. Thus, a scalable,
large scale platform for cardiomyocyte production would
have to emphasize hPSC expansion rather than cardio-
myocyte expansion.Expansion of human pluripotent cells
Prior to establishment of a working cell bank and expan-
sion method, it is important to select robust hPSC lines for
growth ability and cardiomyocyte differentiation. Especially
during the screening of hiPSC clones, it would be ideal to
include parameters used in the later expansion as part of
the selection criteria. For example, if microcarriers are
chosen for hiPSC expansion, then suitable hiPSC clones
should also be tested on microcarriers for cell growth and
expression of pluripotent markers. In our group, we have
observed variability in expansion capability of hPSCs as well
as cardiomyocyte differentiation efficiency. Moreover, the
mode of cell expansion (for example, feeder cells or extra-
cellular matrix (ECM) coating) can affect cardiomyocyte
differentiation efficiency. Hence, it is important to verify
these effects before large scale cardiomyocyte generation.
As shown in Figure 1, three hPSC expansion platforms
are available. To evaluate these different hPSC expansion
platforms for cardiomyocyte generation, we will examine
Figure 1 Bioprocessing of human pluripotent stem cell-derived cardiomyocytes. Illustrations showing phase contrast images of (a) two-dimensional
human embryonic stem cell colony culture in mTeSR™1 medium and (b) human embryonic stem cell-derived beating cardiomyocytes (encircled by the
red line). Scale bars are 200 μm. For small scale production, human pluripotent stem cells (hPSCs) can be expanded from (c) single layer tissue culture flasks
to (d) multilayer flasks (Corning HYPERFlask®) with minimal controls. For clinical and commercial applications, hPSCs can be expanded and differentiated in
suspension as (e) cell aggregates or on (f) microcarriers in bioreactors (g,h) with automated controls. 2D, two-dimensional; EB, embryoid body; qRT-PCR,
quantitative reverse transcriptase-polymerase chain reaction.
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on subsequent cardiomyocyte differentiation.
Platforms for human pluripotent stem cell expansion
Two-dimensional tissue culture
Conventional adherent monolayer culture has been widely
utilized for hPSC expansion on either feeder cells or
ECM (for example, Matrigel, BD Biosciences PTE Ltd.,
Singapore, Singapore) coated plates in conditioned medium
or commercial serum-free medium such as mTeSR™1
(Stemcell Singapore PTE Ltd., Singapore, Singapore)
and StemPro®hESC SFM (Life Technologies, Invitrogen
Singapore PTE Ltd., Singapore, Singapore) (Figure 1a,c).
The majority of reported cardiomyocyte differentiation pro-
tocols utilized either hPSCs co-cultured with feeder cells or
on Matrigel with feeder cell-conditioned medium (Table 1).Expansion of hPSCs can be scaled up by using multi-layer
flasks (Figure 1d). These multi-layer plates are currently
utilized as the cell expansion platform according to good
manufacturing practice for supporting cell therapy-related
clinical trials [29]. Rowley and colleagues [29] estimated
that up to 240 billion hPSCs can be produced with
manual handling of 36 multilayer plates. For larger scales,
suspension cultures were recommended (for example,
microcarrier culture; step 1 in Figure 1g,h) [29]. Another
drawback of hPSC expansion in these tissue culture
flasks is the lack of representative sampling and online
process monitoring or controls. This can undermine the
consistency and the quality of the cells. Moreover, the
production process requires extensive manual handling and
large clean room facilities, which make large scale produc-
tion expensive.





Biomolecules Purity Scalability Comments Reference
Monolayer on feeders
or Matrigel
Monolayer Activin A, BMP4, VEGF, SCF, WNT3a 24% (Nkx 2.5) + [25]
BMP2, 5% FBS 41.6% (cTnT) + [30]
Activin A, BMP4 51% (MHC) + [10]
Activin A, BMP4, DKK1 54.2% (cTnT) + [31]
Activin A, BMP4, FGF2 , VEGF, DKK1 57.2% (cTnT) + [32]
Activin A, BMP4 60% (α-actinin) + [33]
Activin A, BMP4, IWP-4 or IWR-1 60.6% (MHC) + [34]
Activin A, BMP4, FGF2, Noggin, BMS-189453, DKK1 73.0% (cTnT) + [35]
BMP4, ascorbic acid, CHIR99021, IWR-1 80% (cTnT) + [36]
Activin A, BMP4, FGF2 80% (cTnT) + [27]
Activin A, BMP4, VEGF 85.4% (cTnT) + [37]
CHIR99021, IWP-2/IWP-4 88.3% (cTnT) + [38]
FBS 90% (cTnT) + [39]
CHIR99021, BIO, KY02111, XAV939 97.7% (cTnT) + [40]
Embyoid bodies Activin A, FGF2 23.6% (beating EBs) ++ Forced aggregation [41]
Normoxic 48.3% (beating EBs) ++ Micropatterned; controlled bioreactor [42]
BMP4 95.8% (beating EBs) + Replated after 4 days [43]
Ascorbic acid 6.94% (cTnT) + Replated after 5 days [44]
BMP4, IWP-1 15.6% (cTnT) + Replated after 4 days [45]
SB203580 16% (MHC) ++ [28]
SB203580 22.0% (MHC) ++ [46]
BMP2, 5-azacytidine 23.7% (cTnT) + Replated after 6 days [47]
SB203580 26% (MHC) ++ [48]
Activin A, BMP4, FGF2, VEGF, SCF 26.8% (Nkx 2.5) ++ Forced aggregation [24]
Activin A, BMP4, FGF2, VEGF 27.1% (MHC) + Replated after 4 days [49]
Activin A, BMP4, FGF2, VEGF, DKK1 37.2% (cTnT) ++ [50]
WNT3a 50% (α-actinin) + Replated after 6 days [51]
















Table 1 Methods for cardiomyocyte differentiation from human pluripotent stem cells, ranked by purity of yields (Continued)
CHIR99021, IWP-2 60% (cTnT) ++ Unpublished
data
Activin A, BMP4, FGF2, VEGF, DKK1 60.2% (cTnI) ++ [53]
Activin A, BMP4, FGF2 , VEGF, DKK1 82% (cTnT) ++ [23]
BMP4,FGF2 82.3% (cTnI) ++ Forced aggregation [54]
Activin A, BMP4, FGF2, VEGF,DKK1 91.6% (cTnT) ++ Dissociated EBs [55]
Microcarriers SB203580 20% (MHC) +++ [28]
Cell aggregate Monolayer Activin A, BMP4, FGF2 80% (cTnT) + [27]
Embryoid bodies Activin A, BMP4, FGF2, VEGF, DKK1 27% (cTnT) +++ [56]
BMP4 36.9% (Nkx 2.5) + hESC encapsulation [57]
Activin A, BMP4, FGF2, VEGF, IWR-1 80% (cTnT) +++ Controlled bioreactor [27]
Microcarriers No data
Microcarriers Microcarriers CHIR99021, IWP-2 67% (cTnT) +++ Unpublished
data
BMP, bone morphogenetic protein; cTnI, cardiac troponin I; cTnT, cardiac troponin T; EB, embryoid body; FBS, fetal bovine serum; FGF, fibroblast growth factor; hESC, human embryonic stem cell; hPSC, human
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Cell aggregate culture has been developed as a scalable ex-
pansion platform for hPSCs, which utilizes the characteris-
tic of hPSCs to form aggregates in suspension. hPSCs in
single cell suspension usually undergo apoptosis or anoikis.
In order to prevent these detrimental effects and establish a
viable hPSC suspension culture, hPSCs are partially dissoci-
ated in order to form cell aggregates and/or ROCK-Myosin
signaling pathway inhibitors (Y27632 or Blebbistatin) are
added to improve survival of dissociated hPSCs. Despite
significant cell loss during the initial cell aggregate forma-
tion (28 to 76%), several groups have obtained cell concen-
trations of 1 to 2 × 106 cells/ml with 12.5- to 17.7-fold
expansion using various hPSC lines [56,58-60]. Since hPSC
aggregation is usually associated with spontaneous differen-
tiation, maintaining pluripotency can be demanding. Exces-
sive cell aggregation can induce spontaneous differentiation
or necrosis due to nutrient diffusion limitation. The
maintenance of aggregate culture is usually carried out by
limiting aggregate size to under 500 μm by constant disag-
gregation of the culture. The process is done manually and
can affect culture viability and reproducibility. Designing a
scalable bioprocess for aggregate culture may require the
integration of reproducible, automated processes for repeti-
tive dissociation and formation of uniform cell aggregates.
hPSC aggregate cultures were recently reviewed by O'Brien
and Laslett [61].
Microcarrier culture
The development of the microcarrier platform for hPSC
expansion has attracted interest for generating cardiomyo-
cytes in a scalable manner. hPSCs cultured on microcarriers
exhibited higher cell density and expansion than two-
dimensional tissue or aggregate cultures, while maintaining
pluripotency and karyotypic stability [62]. A recent study by
Bardy and colleagues [63] reported the highest cell concen-
tration of 6.1 × 106 cells/ml with 20-fold expansion in
spinner flasks in serum-free medium. The microcarrier-
expanded cells exhibited the capacity to differentiate in situ
to neural progenitors [63], endoderm progeny [64], and car-
diomyocytes [62,65]. However, in order to establish a viable
hPSC microcarrier culture, several factors have to be consid-
ered, such as microcarrier coating and type, bioreactor
design, operating parameters and feeding of medium. These
factors can have significant impacts on cell growth, pluripo-
tency and lineage commitments [66]. Compared to other
classical microcarrier cultures (for example, Vero cells and
mesenchymal stem cells) that form monolayers of cells on
microcarriers, hPSCs form multi-layered cell-microcarrier
aggregates during propagation. Several groups have screened
a variety of microcarriers and coatings for initial cell attach-
ment and hPSC expansion and examined their impact on
prolonged cultivation [64,65,67,68]. A study by Chen and
colleagues [67] examined in detail the effects of shape, size,surface charge, and coatings of microcarriers on hPSC culti-
vation. Microcarrier shape and size affect the compactness
of cell-microcarrier aggregates and consequently
cell growth. hPSCs cultured on spherical microcarriers
(Ø >180 μm) exhibited more open structures whereas
compact cell-microcarrier aggregates were observed in
cylindrical microcarriers [67]. The compactness of cell-
microcarrier aggregates increased with the decrease in
microcarrier diameter and this had a negative impact on cell
growth, likely due to limited nutrient diffusion for the cells
within the aggregates [67]. Matrigel coating has been shown
to be critical for hPSC cultivation on microcarriers. Recently,
it was shown that laminin and vitronectin can replace
Matrigel as defined coatings on microcarriers without
compromising cell growth [69]. ROCK inhibitors (Y27632
or Blebbistatin) were later shown to enable hPSC growth on
ECM coating-free microcarriers [70].
Scaling up of hPSC microcarrier cultures has been
demonstrated by several groups using spinner flasks. Serra
and colleagues [71] carried out hPSC microcarrier culturing
in bioreactors (300 ml) with automated process control.
The authors achieved 2.17 × 106 cells/ml in 11 days with a
seeding density of 1.5 × 105 cells/ml (15-fold expansion). A
comprehensive review of the bioprocess parameters for
hPSC microcarrier culture was recently published [66]. It is
important to note that hPSCs propagated on microcarriers
can undergo changes in their phenotype. hPSCs cultured
on microcarriers exhibited longer doubling time and a gen-
erally lower lactic acid specific production rate than those
cultured on a tissue culture plate in serum-free media [72].
Leung and colleagues [73] reported different sensitivities of
hPSC lines to shear stress. hPSCs expanded on micro-
carriers in spinner flasks were able to differentiate efficiently
to neural progenitors [63] and endoderm progeny [64].
However, this was not the case for cardiac differentiation.
We have observed that hPSCs expanded in agitated micro-
carrier cultures and differentiated to cardiomyocytes by the
p38 MAP kinase protocol [28,74] exhibited lower yields of
cardiomyocytes when compared to cells expanded in static
microcarrier culture (unpublished results). We hypothesized
that the shear effect caused subtle changes in hPSCs that
reduced their cardiac differentiation propensity. Hence, it is
important to establish quality controls to monitor these sub-
tle changes in hPSC culture before cardiac differentiation.
Cardiogenesis
Cardiomyocyte differentiation is based on the recapitulation
of in vivo cardiogenesis, which depends on a series of
complex molecular signaling pathways [75,76]. The differen-
tiation efficiency of these methods depends on the biomole-
cules used (growth factors or small molecule inhibitors),
hPSC culture expansion conditions and the timely activation
or deactivation of molecular signals necessary to guide
the differentiation toward cardiac lineages (Figure 2) [77].
Figure 2 Schematic of human pluripotent stem cell expansion and differentiation to cardiomyocytes. Biomolecules (growth factors and small
molecules) play important roles in human pluripotent stem cell (hPSC) expansion and differentiation to cardiomyocytes. Intracellular and cell surface
markers associated with each of the three main stages can be used to monitor the progression of differentiation.
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of growth factors or small molecule inhibitor treatments
depend on the platform (embryoid body (EB), two-
dimensional tissue culture or microcarrier cultures) and the
hPSC line.
Current cardiac differentiation protocols use either small
molecule inhibitors or growth factors to induce the signals
for cardiac differentiation. In both cases, the signaling leads
to a cascade of three sequential stages: mesodermal induc-
tion, cardiac progenitor and cardiomyocyte generation and
maintenance [78] (Figure 2). Mesodermal induction, which
is monitored by the expression levels of KDR and PDGFR-α
[23,53], takes place during the first 3 to 4 days of cardio-
myocyte differentiation. This step is usually induced with
the growth factors, bone morphogenetic protein (BMP)4
and Activin A, which activate the transforming growth
factor (TGF)-β signaling pathway, which is crucial for meso-
derm differentiation [79]. Mesoderm induction can be also
achieved by the addition of small molecules, such as
GSK-3β inhibitors (CHIR99021 or BIO) [38,40]. These
inhibitors increase endogenous levels of BMP2/4, thus indir-
ectly activating the TGF-β signaling pathway [38].
Cardiac progenitor induction is achieved by removal of
the TGF-β pathway activators and addition of the growth
factors, fibroblast growth factor-2 and/or vascular endothe-
lial growth factor, which activate the ERK signaling pathway
[80], or by small molecules that inhibit WNT signaling (for
example, KY02111, XAV939, IWP-2 and IWR-1). As these
factors drive mesodermal cells towards the cardiac progeni-
tor lineage, they inhibit the development of smooth muscle
and endothelial cell lineages [32,50]. A common finding in
this stage is that the addition of insulin inhibits the cardiac
progenitor differentiation process [49].
The final stage of cardiomyocyte production (day 8 and
later) focuses on maturation of cells to cardiomyocytes and
their maintenance. Differentiated cardiomyocytes can bemaintained in simple serum-free medium, which can
minimize outgrowth of fibroblasts and maintain cardio-
myocyte purity. Prolonged cultivation of cardiomyocytes
has been shown to increase the amount of mature ventricu-
lar phenotype [38].
Current platforms for generating cardiomyocytes
from human pluripotent stem cells
After having established a scalable hPSC expansion
method, a suitable cardiac differentiation process should be
developed. The variety of protocols used by research groups
indicates the complexity of the differentiation process and
hence the difficulty of applying universally efficient differen-
tiation protocols to the different hPSC lines and culture
conditions (Table 1). To date, cardiomyocyte differentiation
platforms can be divided into three categories, namely
monolayer, EB and microcarrier cultures. Selecting a suit-
able platform for cardiomyocyte production may depend
on several factors, including type of intended application
(for example, cell therapy, disease modeling, cardiac
toxicology study).
Two-dimensional tissue culture
In the two-dimensional tissue culture differentiation plat-
form, hPSCs expanded in monolayer can be directly differ-
entiated to cardiomyocytes by a simple change of hPSC
growth medium to cardiac differentiation medium. The
first efficient directed differentiation protocol was reported
by co-culturing hESCs with mouse endoderm-like cells
(END-2), which generated 85% cells exhibiting ventricular-
like action potentials [81]. Differentiation protocols were
further refined by using more defined conditions with
known growth factors, extracellular matrices and eliminat-
ing the need for END-2 cells. As shown in Table 1, a simple
protocol of using serum-free medium supplemented with
Activin A and BMP4 can direct the differentiation to
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hPSC monolayer culture for 1 day, then BMP4 for 4 days
followed by the removal of growth factors and maintenance
in serum-free medium afterward [10]. The protocol was
further improved with additional growth factors or small
molecules to accommodate interline variability that usually
exists among hPSC lines. Recently, small molecules target-
ing TGF-β, BMP and WNT signaling have shown the
potential to replace growth factors in directing hPSC to car-
diomyocytes [38]. In particular, small molecules targeting
WNT signaling were the most promising. The sequential
activation of WNT via GSK-3β inhibitors (for example,
CHIR99021 and BIO) for 1 day, followed by WNT inhib-
ition (for example, KY02111, XAV939, IWP-2 and IWR-1)
at day 3 and removal of small molecules after day 5
achieved cardiomyocyte purity of up to 98% at day 14 [38].
Prolonged cultivation or using the novel WNT inhibitor
KY02111 generated more ventricular cardiomyocytes
[38,40]. These molecules have been applied successfully in
cardiomyocyte differentiation using hPSCs cultured on
synthetic ECM peptide coated plates [38].
Embryoid body culture
In the EB differentiation platform, cells from two-
dimensional cell cultures are usually dissociated into single
cells followed by re-aggregation in order to generate homo-
geneous EB cultures with uniform sizes that are further dif-
ferentiated to cardiomyocytes (Figure 1e). In general, this
dissociation process can lead to significant cell death [82].
Differentiating hPSCs as EBs was first employed in order to
accurately recapitulate the complex assembly of cell adhe-
sion and intracellular signaling of early embryogenesis [82].
hPSCs undergo spontaneous differentiation when cultured
in suspension as EBs, forming cells of the three lineages.
Without guidance towards cardiomyocyte differentiation
and control of the culture conditions, the efficiency of
cardiomyocyte differentiation was usually low (<1%) [30].
Significant progress has been made to improve EB-based
cardiomyocyte differentiation efficiency with the identifica-
tion of growth factors and pathways associated with cardiac
differentiation (Table 1). Most of the reported EB cultures
use hPSCs expanded in two-dimensional tissue cultures on
feeder cells, in particular mouse embryonic fibroblasts.
Upon cell dissociation, the residual feeder cells in the cell
suspension provide attachment matrices for the generation
of EBs. These EBs achieve higher cell viability and aggregate
stability compared to EBs generated from two-dimensional
tissue cultures without feeder layers (for example, Matrigel)
[83].
EB differentiation protocols are more complicated than
those used in two-dimensional tissue cultures due to their
three-dimensional shape and the effects of the EB micro-
environment [82]. Specifically, the size of EBs has been
shown to influence cell differentiation towards differentlineages [84]. In addition, concentrations of small molecules
or growth factors used for differentiation had to be adjusted
as these soluble factors have to diffuse through a multi-
layered cell environment [82]. As cells differentiate toward
the cardiac lineage, the formation of excessive aggregate
size as a result of cell proliferation or attachment of several
aggregates into one (agglomeration) could cause necrosis
and consequently reduce cardiomyocyte yield [74]. In order
to overcome these problems, several groups have placed
single dissociated cells into V- or U-bottom micro-wells
coupled with centrifugation to generate uniform cell-
aggregates with cell numbers ranging from 200 to 1,000
cells per aggregate [53,58]. Others have tried encapsulation
of hESCs and differentiation to cardiomyocytes [57]. We
have tested the use of inert dextran beads as a means to
separate cell aggregates from each other. In brief, dextran
beads were added to culture wells containing EBs to fill
spaces between aggregates, forming two to three layers of
beads. Without these inert beads separating the aggregates,
frequent manual manipulation of cell aggregates is required
in order to prevent agglomeration [74]. In some cases,
4-day-old EBs can be plated on ECM-coated tissue culture
plates (for example, gelatine), forming beating cell layers
afterward. Under these culture conditions, the yield and
purity of the cardiomyocytes improved significantly,
achieving 64 to 89% cardiac troponin T (cTnT)-positive
cardiomyocytes with a variety of hPSC lines [54].
Furthermore, hPSCs can be expanded as cell aggregates
in suspension without microcarriers as discussed previ-
ously. Two studies showed that these aggregate cultures ex-
panded in a spinner flask can be subsequently differentiated
in situ to cardiomyocytes as EBs [56,58]. Matsuura and col-
leagues [27] reported 80% cTnT-positive cardiomyocytes
generated in a controlled bioreactor. Even though the
efficiency of cardiomyocyte differentiation was lower than
some of the reported EB-based methods (Table 1), cell ag-
gregate expansion followed by in situ differentiation is more
scalable than monolayer expansion.
Microcarrier platform
Microcarriers can be applied in two ways for cardiomyocyte
differentiation. Firstly, they can be used to assist EB forma-
tion, stabilization and prevention of agglomeration. Lecina
and colleagues [28] used five different microcarriers to
examine the effect of microcarrier type, size, shape and
concentration on the efficiency of EB-based cardiomyocyte
differentiation using SB203580, a mitogen-activated protein
kinase inhibitor. Only the small positively charged Tosoh-
10 beads of Ø10 μm, which did not support cell expansion
[67], were able to stabilize EB structures and achieve effi-
cient cardiomyocyte differentiation. Using these microcar-
riers, a cardiomyocyte yield of 90% beating aggregates and
17% cells expressing cardiomyocyte markers (myosin heavy
chain and alpha-smooth muscle actin) were achieved in
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higher efficiency (0.28 to 0.62 cardiomyocytes generated
per hESC seeded) than the EB-based method (0.13 to 0.22
cardiomyocyte generated per hESC seeded) was achieved
[28,74]. Conventional larger microcarriers (Cytodex1 (Ø190
μm) and DE-53 (length 130 μm×diameter 35 μm)) that ex-
hibited higher hPSC expansion capability were not efficient
in generation of beating cell-microcarrier aggregates during
the cardiomyocyte differentiation process.
In a second approach, hPSC microcarrier aggregates gen-
erated during cell expansion can be directly differentiated
to cardiomyocytes [62,65]. Reported experimental results
using this approach are still limited. However, our group
has applied microcarrier expanded hPSC cells for cardio-
myocyte differentiation and obtained high cell density of
8 × 106 cells/ml (40.4-fold cell expansion) with high cardio-
myocyte purity of 67% cTnT and yields of 268 cardiomyo-
cytes per hPSC seeded (Figure 1f; unpublished data).
Furthermore, we have observed that the method of hPSC
microcarrier culture expansion (static versus agitated con-
dition in spinner flask) can affect the efficiency of cardio-
myocyte differentiation. The cause for this phenomenon is
still under investigation.
Considerations for scaling up cardiomyocyte
production
We have analyzed three hPSC expansion platforms (two-
dimensional, cell-aggregate and microcarrier cultures) for
their potential to be coupled with various differentiation
platforms. These platforms can be applied using a variety of
media, culture methods and conditions. In the following
section we discuss critical criteria that should be considered
in selection of conditions for designing a scalable cardio-
myocyte production system.
Selection of cardiomyocyte production platform
The selection of cardiomyocyte production platform is
dictated by the quantity of cardiomyocytes required for a
particular application. Three methods of hPSC expansion
and seven options for cardiomyocyte differentiation are avail-
able for cardiomyocyte production (Table 1). The initial se-
lection of hPSC expansion platform would be based on the
amount of cardiomyocytes and the purity needed. The
monolayer culture platform can be considered the most
straightforward method when compared to suspension-
based systems, achieving relatively high differentiation
efficiency (Table 1). For large scale production purposes,
cell-aggregate and microcarrier-based systems should be
considered. Furthermore, process monitoring and control
can be easily applied in suspension platforms to ensure
process consistency and reproducibility (Figure 1g,h). We be-
lieve the integration of hPSC expansion and cardiomyocyte
differentiation as a one unit operation in suspension would
be the best approach to scale up cardiomyocyte production.Bioprocess parameters for cardiomyocyte production in
suspension
hPSC expansion in suspension with automated online
process monitoring and controls has been reported [71].
Serra and colleagues [71] examined the effects of oxygen
and operation mode (perfusion versus semi-continuous) in
hPSC microcarrier cultures [71]. Oxygen was preferable at
30% air saturation instead of 5%. hPSCs in perfusion mode
(dilution rate of 0.5 day-1) showed lower lactate production
and shorter lag phase than semi-continuous culture (50%
medium exchange per day) [71]. The perfusion system
might be ideal for stage-specific cardiomyocyte differenti-
ation compared to current processes with constant fluctua-
tions in metabolite and growth factor concentrations. Such
a system with optimized medium feed can also provide
greater efficiencies, replacing current empirical media
feeding schemes for hPSC expansion and cardiomyocyte
differentiation.
Maintaining a homogeneous suspension culture is critical
in process monitoring and controls, but can be challenging
considering the size variations of cell aggregate and cell-
microcarrier aggregate cultures. Stirring can also induce
shear stress responses. Recently, we have observed that
agitation-induced shear stress in spinner microcarrier
cultures reduced cardiomyocyte differentiation efficiency.
Applying agitation during the first 3 days of cardiomyocyte
differentiation (for both microcarrier- and EB-based
methods) suppressed cardiomyocyte differentiation. This
inhibition could be alleviated when intermittent agitation
was employed. The literature reports that shear stress
affects the TGF-β pathway, which is vital in cardiomyocyte
differentiation [85,86].
Medium development
Medium development is critical in the development of hPSC
expansion and differentiation processes. In most papers,
hPSCs were expanded in conditioned medium on Matrigel-
coated plates or mitotically inactivated feeder cells (Table 1).
Medium components like serum replacement (Knockout
Serum Replacement (KOSR, Life Technologies)), feeder cells
and Matrigel for coating of plates or microcarriers pose risks
of pathogen contamination. Therefore, defined xeno-free
conditions for hPSC expansion have been developed. Lately,
it was reported that hPSCs can be cultured in a simple
xeno-free, defined medium with eight components on
recombinant vitronectin coated plates [87]. This defined and
cheaper medium has significant impact on future hPSC
clinical applications where the high medium cost has been
one of the bottlenecks for studying large scale process devel-
opment. This medium can also be adapted for hPSC expan-
sion in aggregate or microcarrier cultures. Significant
progress has also been made in establishing defined media
for each stage of cardiomyocyte differentiation. Media used
by various groups are relatively defined and include known
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of serum albumin (bovine or human) added. Serum-
supplemented medium has been used by several groups in
generating stable EBs (Table 1). To tackle this issue, Ng and
colleagues [88] developed a defined medium, denoted as
APEL, for EB formation and differentiation. To address the
cost efficiency, small molecules that target WNT signaling
transduction pathways have been found to be suitable
replacements for costly growth factors.
Downstream processing
Studies on development and optimization of downstream
processing of hPSC-derived cardiomyocytes are very lim-
ited. The process of harvesting cardiomyocytes from mono-
layer, EB or microcarrier cultures has been demonstrated
for small scale research purposes. Monolayer cultures, EBs
or cell-microcarrier aggregates are treated with dissociation
enzymes followed by passing through a sieve to remove
undissociated cell aggregates and microcarriers [74]. These
processes are usually not optimized and can become more
problematic during scaling up. Enzyme concentration,
treatment time, mode of mixing, and sieve loading capacity
can affect cell viability and harvest efficiency. Hence, there
is a need for further investigation into establishing a
scalable and efficient cell harvesting process.
Another aspect of downstream processing is the purifica-
tion of cardiomyocytes from mixed cell populations [31,89].
Considering the amount of cells required for cell therapy,
the effects of unwanted cells in cell replacement therapy
are largely unknown. Tumorigenicity related to undifferen-
tiated hPSCs remains one of the main concerns, which can
be addressed by two approaches. Choo and colleagues [90]
used cytotoxic monoclonal antibodies against hPSCs to
eliminate undifferentiated hPSCs. Others reported the use
of magnetic activated micro-beads coupled to multiple anti-
bodies to remove undifferentiated hPSCs and enrich cardi-
omyocytes from the heterogeneous cell population after
differentiation [31,89,91,92]. However, the antibody-based
approach might not be economically viable when scaled up
due to the quantity of antibodies needed and their
associated costs. Alternatively, Tohyama and colleagues
[93] showed a novel approach based on cardiomyocyte
metabolic properties, in which cardiomyocytes (up to 99%
purity) were selected from mixed cell populations using
glucose-depleted medium containing high lactate. This
method is inexpensive, scalable and could be easily
integrated into a cardiomyocyte production platform. In
addition, hPSC-derived cardiomyocyte cultures contain
three sub-phenotypes (atrial, ventricular and nodal). The
ratio between these subtypes can be altered by modulating
signaling pathways during the differentiation [78]. It was
reported that activation of neuregulin/ErbB signaling can
increase the nodal fraction within the cardiomyocyte popu-
lation [94]. Overexpression of microRNA 499, decreasedretinoid signaling, electrical stimulation, prolonged cultiva-
tion and use of the WNT inhibitor KY02111 were shown
to increase the ventricular subtype [35,38,40,95,96]. Thus,
isolation and purification of the required sub-phenotype
could be further investigated in order to improve efficiency.
Specifically, enriched nodal cells could potentially form a
biological pacemaker whereas ventricular cardiomyocytes
could be used for cell therapy after ventricular myocardial
infarction.
Lastly, the purified cardiomyocytes can be either cryo-
preserved or applied directly for tissue engineering. Pro-
gress has been made showing the functionality of
cryopreserved and dissociated cardiomyocytes. A study by
Xu and colleagues [97] showed that cardiomyocytes can
be dissociated into single cells, cryopreserved and thawed
without significant loss (70-77% recovery). These cells
could be used for transplantation, comparable to freshly
isolated cells [97].
Meeting current good manufacturing practice requirements
Production of cardiomyocytes at clinical commercial
scales that follows the current good manufacturing
practice (cGMP) standard will be challenging as most of
the current processes are carried out for research
purposes without any consideration for cGMP require-
ments. A defined xeno-free integrated process of
expansion, differentiation and downstream purification
within a closed system with appropriate monitoring and
control systems would be the most suitable for cGMP
manufacturing. To characterize the cardiomyocytes
produced, quality control assays (step 3 in Figure 1)
should be standardized to include cardiomyocyte gene
(for example, quantitative RT-PCR) and protein marker
(flow cytometry and immunocytochemistry) expression
analysis, characterization of electrophysiological properties
(multi-electrode array and patch clamp), structural
property and organization (electron microscopy) analysis,
and determination of calcium signaling (calcium imaging)
[98]. Automated high-throughput imaging-based assays
developed recently can be advantageous for providing
reliable, non-invasive, multi-parameter, real-time monitor-
ing of cardiomyocytes in suspension as EBs or on
microcarriers. In cases where downstream purification of
cardiomyocytes to subtypes is performed, quality control
of cell identity should be done by using the whole cell
patch clamping technique, high content immunocyto-
chemistry and flow cytometry [78]. Patch clamping
measures the action potential of individual cells and can
be both time consuming and low throughput. Flow
cytometry analysis using antibodies against these subtypes
has been utilized as a high-throughput method. Anti-
bodies against myosin light chain 2 (MLC2) isoforms,
namely MLC2a and MLC2v, are widely used to determine
ventricular and atrial-like cardiomyocytes.
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Cardiac differentiation is an extremely delicate and dynamic
process that involves the activation and inhibition of
multiple signaling pathways at different time points. Due to
this complexity, the development of a protocol that can effi-
ciently differentiate hPSCs to cardiomyocytes in a scalable
platform has still yet to be developed and optimized. In this
review, current platforms for hPSC expansion have been
reviewed for their propensity to be adapted into a scalable
bioprocess and their efficiency in terms of cardiomyocyte
differentiation. The different protocols developed over the
past few years have focused on generation of high purity
cardiomyocytes without considering issues involved in
scaling up the processes. Establishment of a scalable cardio-
myocyte production platform requires a more holistic
approach integrating parameters related to scaling up hPSC
expansion, cardiomyocyte differentiation and downstream
purification into a one unit operation.
In summary, current demands from regenerative medi-
cine, drug testing, and disease modeling require develop-
ment of cardiomyocyte production processes that have to
meet a variety of requirements (for example, serum-free
media, cGMP requirements, cost of production, quality con-
trol and downstream bioprocessing). Beyond these issues,
several others have to be considered in future applications.
For example, cardiomyocytes produced according to the
current methods are immature in their marker expression
and electrical and mechanical functionality [77]. This poses
problems for the applications mentioned previously as im-
mature cardiomyocytes may not be the most ideal models
of adult cardiomyocytes. Moreover, for cell therapy an ap-
propriate cell delivery method should be developed [77,99].
These challenges call for multidisciplinary efforts that adapt
current cardiomyocyte differentiation protocols to develop a
cost-effective, scalable and cGMP compliant process, and
that resolve issues of downstream purification and quality
control as well as cell maturation and delivery systems.Note: This article is part of a thematic series on Cardiovascular
regeneration edited by Ronald Li. Other articles in the series can
be found online at http://stemcellres.com/series/cardiovascular.Abbreviations
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